Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:36:37.270Z.
Calculation as of: 2026-10-06T15:36:37.270Z.
Quote observation: 2026-10-06T15:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$676.45M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$670.12M
Price/FCF Ratio
16.52
TTM Avg
12.94
3Y Avg
32.63
5Y Avg
32.63
Market Cap
$702.99M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$640.40M
Price/FCF Ratio
N/A
TTM Avg
3847.94
3Y Avg
3847.94
5Y Avg
3847.94
Market Cap
$713.63M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $676.45M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.12M | 16.52 | 12.94 | 32.63 | 32.63 |
| Helus Pharma Inc. (HELP)vs › | $684.61M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $691.60M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $702.99M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $645.85M | N/A | 697.87 | 748.88 | 748.88 |
| Aura Biosciences, Inc. (AURA)vs › | $647.51M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $640.40M | N/A | 3847.94 | 3847.94 | 3847.94 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.63M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $722.58M | 2.20 | 4.81 | 5.21 | 6.10 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
